Nektar's Rezpegaldesleukin Shows Significant Efficacy in Treating Alopecia Areata
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
Source: Newsfilter
Nektar Therapeutics' stock surged by 17.36% in pre-market trading, reaching a 52-week high, following the announcement of significant efficacy results from its REZOLVE-AA clinical trial for Rezpegaldesleukin in treating alopecia areata.
The trial results indicated that 29% and 31% of patients in the 18 µg/kg and 24 µg/kg dose groups achieved a SALT score ≤20, showcasing the drug's potential. Additionally, a high completion rate of 94% among participants and a favorable safety profile further enhance the drug's market prospects, positioning Nektar favorably in the biotechnology sector.
These promising results not only highlight the effectiveness of Rezpegaldesleukin but also suggest a strong market demand for new treatments for alopecia areata, potentially leading to increased investor interest and confidence in Nektar's future developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 73.150
Low
102.00
Averages
123.43
High
165.00
Current: 73.150
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nektar to Launch Global Late-Stage Eczema Study
- Eczema Study Progress: Nektar plans to initiate its global late-stage program for moderate-to-severe atopic dermatitis by the end of July 2026, testing a specific dose every two weeks to gather data for regulatory approval, with initial results expected around mid-2028.
- Alopecia Areata Results: In April 2026, Nektar reported positive mid-stage study results for alopecia areata, indicating stronger responses in severe patients, and plans to meet with the FDA in Q2 2026 to discuss larger late-stage trials.
- Strong Financial Position: Nektar ended Q1 2026 with over $1 billion in cash and investments, providing sufficient runway to advance its lead drug into 2028 without the need for immediate new funding.
- Market Sentiment Shift: NKTR stock sentiment shifted from 'bearish' to 'bullish' among retail traders in the past 24 hours, reflecting optimism about the company's future, although some users noted a lack of significant announcements recently.
See More
Nektar to Launch Global Late-Stage Atopic Dermatitis Trials by July 2026
- Atopic Dermatitis Trials Launch: Nektar plans to initiate its global late-stage program for moderate-to-severe atopic dermatitis by the end of July 2026, aiming to gather regulatory approval data through bi-weekly dosing, with initial results expected around mid-2028.
- Alopecia Areata Progress: In April 2026, Nektar reported positive mid-stage study results for alopecia areata, indicating stronger responses in severe cases, and plans to meet with the FDA in Q2 2026 to discuss larger late-stage trials.
- Strong Financial Position: Ending Q1 2026 with over $1 billion in cash and investments, Nektar's robust financial health provides sufficient runway to advance its lead drug into 2028 without the immediate need for new funding.
- Market Sentiment Shift: Retail sentiment around Nektar stock shifted from 'bearish' to 'bullish' in the past 24 hours, reflecting investor optimism about the company's future, although some users noted a lack of significant announcements that could dampen momentum.
See More
Nektar Grants Stock Options and RSUs to New Employees
- Stock Option Grant: On June 19, 2026, Nektar Therapeutics granted 20,500 stock options and 3,900 restricted stock units (RSUs) to seven newly hired employees, highlighting the company's commitment to attracting talent and incentivizing new hires.
- Incentive Plan Background: This grant is part of Nektar's 2025 Inducement Plan, adopted on November 6, 2025, aimed at providing equity awards to individuals who were not previously employed by the company, aligning with Nasdaq listing rules and demonstrating strategic talent acquisition efforts.
- Option Terms Details: The stock options have an exercise price of $60.98 per share, equal to the closing price on June 18, 2026, with an eight-year term and a four-year vesting schedule, reflecting the company's recognition of long-term employee contributions.
- RSU Vesting Arrangement: The RSUs also vest over four years, with 1/4 vesting after the first year and 1/16 vesting quarterly thereafter, ensuring employees remain with the company to receive their rewards, thereby enhancing employee loyalty and stability.
See More
Nektar Grants Stock Options and RSUs to New Employees
- Stock Option Grant: On June 19, 2026, Nektar Therapeutics granted a total of 20,500 non-qualified stock options and 3,900 restricted stock units (RSUs) to seven newly hired employees, aimed at attracting top talent and enhancing the company's competitiveness.
- Incentive Plan Background: This grant is based on Nektar's 2025 Inducement Plan adopted on November 6, 2025, which is specifically designed for individuals who have not previously worked for Nektar, complying with Nasdaq listing rules, demonstrating the company's commitment to talent acquisition.
- Option Exercise Price: The stock options have an exercise price of $60.98 per share, equal to Nektar's common stock closing price on June 18, 2026, reflecting the company's confidence in future stock performance while providing attractive incentives for new employees.
- Vesting Arrangement: Both the stock options and RSUs vest over four years, with 1/4 vesting after the first year and the remainder vesting monthly or quarterly, ensuring employee retention and loyalty, thereby enhancing workforce stability.
See More
Nektar Therapeutics CEO Sells 20,000 Shares in Open Market Transactions
- Insider Trading: Howard W. Robin, CEO of Nektar Therapeutics, sold 20,000 shares between June 16 and 17, 2026, totaling approximately $1.22 million, indicating a consistent selling pattern aligned with his historical transactions.
- Shareholding Proportion: This sale represents 26.64% of Robin's direct holdings, reducing his direct share count from 75,073 to 55,045, reflecting confidence in the company's future prospects despite the sale.
- Improved Financial Position: Nektar ended Q1 2026 with $731.6 million in cash and investments, later adding approximately $351 million from an April stock offering, providing substantial resources for ongoing R&D efforts.
- R&D Progress Outlook: Despite reporting a net loss, the company saw a slight revenue increase to $10.9 million in Q1, and the anticipated Phase 3 trial for its lead candidate, rezpegaldesleukin, expected to start in July, could significantly impact its future growth trajectory.
See More
Nektar Grants Stock Options to New Employees
- Stock Option Grant: On May 20, 2026, Nektar Therapeutics granted a total of 11,900 non-qualified stock options to five newly hired employees, aimed at attracting top talent and strengthening the team.
- Incentive Plan Background: This stock option grant is based on Nektar's 2025 Inducement Plan adopted on November 6, 2025, specifically designed for individuals who were not previously employed by the company, in compliance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Setting: The stock options have an exercise price of $69.49 per share, which aligns with the closing price on the grant date, a strategy that helps ensure employees' interests are closely tied to the company's stock performance.
- Long-term Incentive Mechanism: These stock options will vest over eight years, with 1/4 of the shares vesting on the one-year anniversary and 1/48 vesting monthly thereafter, aimed at promoting employee retention and performance enhancement through long-term incentives.
See More
Nektar to Launch Global Late-Stage Eczema Study
- Eczema Study Progress: Nektar plans to initiate its global late-stage program for moderate-to-severe atopic dermatitis by the end of July 2026, testing a specific dose every two weeks to gather data for regulatory approval, with initial results expected around mid-2028.
- Alopecia Areata Results: In April 2026, Nektar reported positive mid-stage study results for alopecia areata, indicating stronger responses in severe patients, and plans to meet with the FDA in Q2 2026 to discuss larger late-stage trials.
- Strong Financial Position: Nektar ended Q1 2026 with over $1 billion in cash and investments, providing sufficient runway to advance its lead drug into 2028 without the need for immediate new funding.
- Market Sentiment Shift: NKTR stock sentiment shifted from 'bearish' to 'bullish' among retail traders in the past 24 hours, reflecting optimism about the company's future, although some users noted a lack of significant announcements recently.
See More
Nektar to Launch Global Late-Stage Atopic Dermatitis Trials by July 2026
- Atopic Dermatitis Trials Launch: Nektar plans to initiate its global late-stage program for moderate-to-severe atopic dermatitis by the end of July 2026, aiming to gather regulatory approval data through bi-weekly dosing, with initial results expected around mid-2028.
- Alopecia Areata Progress: In April 2026, Nektar reported positive mid-stage study results for alopecia areata, indicating stronger responses in severe cases, and plans to meet with the FDA in Q2 2026 to discuss larger late-stage trials.
- Strong Financial Position: Ending Q1 2026 with over $1 billion in cash and investments, Nektar's robust financial health provides sufficient runway to advance its lead drug into 2028 without the immediate need for new funding.
- Market Sentiment Shift: Retail sentiment around Nektar stock shifted from 'bearish' to 'bullish' in the past 24 hours, reflecting investor optimism about the company's future, although some users noted a lack of significant announcements that could dampen momentum.
See More
Nektar Grants Stock Options and RSUs to New Employees
- Stock Option Grant: On June 19, 2026, Nektar Therapeutics granted 20,500 stock options and 3,900 restricted stock units (RSUs) to seven newly hired employees, highlighting the company's commitment to attracting talent and incentivizing new hires.
- Incentive Plan Background: This grant is part of Nektar's 2025 Inducement Plan, adopted on November 6, 2025, aimed at providing equity awards to individuals who were not previously employed by the company, aligning with Nasdaq listing rules and demonstrating strategic talent acquisition efforts.
- Option Terms Details: The stock options have an exercise price of $60.98 per share, equal to the closing price on June 18, 2026, with an eight-year term and a four-year vesting schedule, reflecting the company's recognition of long-term employee contributions.
- RSU Vesting Arrangement: The RSUs also vest over four years, with 1/4 vesting after the first year and 1/16 vesting quarterly thereafter, ensuring employees remain with the company to receive their rewards, thereby enhancing employee loyalty and stability.
See More
Nektar Grants Stock Options and RSUs to New Employees
- Stock Option Grant: On June 19, 2026, Nektar Therapeutics granted a total of 20,500 non-qualified stock options and 3,900 restricted stock units (RSUs) to seven newly hired employees, aimed at attracting top talent and enhancing the company's competitiveness.
- Incentive Plan Background: This grant is based on Nektar's 2025 Inducement Plan adopted on November 6, 2025, which is specifically designed for individuals who have not previously worked for Nektar, complying with Nasdaq listing rules, demonstrating the company's commitment to talent acquisition.
- Option Exercise Price: The stock options have an exercise price of $60.98 per share, equal to Nektar's common stock closing price on June 18, 2026, reflecting the company's confidence in future stock performance while providing attractive incentives for new employees.
- Vesting Arrangement: Both the stock options and RSUs vest over four years, with 1/4 vesting after the first year and the remainder vesting monthly or quarterly, ensuring employee retention and loyalty, thereby enhancing workforce stability.
See More
Nektar Therapeutics CEO Sells 20,000 Shares in Open Market Transactions
- Insider Trading: Howard W. Robin, CEO of Nektar Therapeutics, sold 20,000 shares between June 16 and 17, 2026, totaling approximately $1.22 million, indicating a consistent selling pattern aligned with his historical transactions.
- Shareholding Proportion: This sale represents 26.64% of Robin's direct holdings, reducing his direct share count from 75,073 to 55,045, reflecting confidence in the company's future prospects despite the sale.
- Improved Financial Position: Nektar ended Q1 2026 with $731.6 million in cash and investments, later adding approximately $351 million from an April stock offering, providing substantial resources for ongoing R&D efforts.
- R&D Progress Outlook: Despite reporting a net loss, the company saw a slight revenue increase to $10.9 million in Q1, and the anticipated Phase 3 trial for its lead candidate, rezpegaldesleukin, expected to start in July, could significantly impact its future growth trajectory.
See More
Nektar Grants Stock Options to New Employees
- Stock Option Grant: On May 20, 2026, Nektar Therapeutics granted a total of 11,900 non-qualified stock options to five newly hired employees, aimed at attracting top talent and strengthening the team.
- Incentive Plan Background: This stock option grant is based on Nektar's 2025 Inducement Plan adopted on November 6, 2025, specifically designed for individuals who were not previously employed by the company, in compliance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Setting: The stock options have an exercise price of $69.49 per share, which aligns with the closing price on the grant date, a strategy that helps ensure employees' interests are closely tied to the company's stock performance.
- Long-term Incentive Mechanism: These stock options will vest over eight years, with 1/4 of the shares vesting on the one-year anniversary and 1/48 vesting monthly thereafter, aimed at promoting employee retention and performance enhancement through long-term incentives.
See More
